An Open-label, Single-arm, Phase I/II Study of Lapatinib in Combination With Weekly Paclitaxel as First-line Chemotherapy for ErbB2-overexpressing Metastatic Breast Cancer Patients.

Trial Profile

An Open-label, Single-arm, Phase I/II Study of Lapatinib in Combination With Weekly Paclitaxel as First-line Chemotherapy for ErbB2-overexpressing Metastatic Breast Cancer Patients.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2014

At a glance

  • Drugs Lapatinib (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 18 Sep 2014 The Primary endpoint assessment (OS) duration changes from "assumption of 2 yrs" to "until death due to any cause or study close, whichever occurred first (assessed up to a maximum of 1290 Days)" according to ClinicalTrials.gov
    • 30 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 01 Feb 2013 Planned End Date changed from 1 Mar 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top